MON – This is an archival post so I can have bragging rights for having predicted that MON will convert the Roundup business to a discontinued operation for GAAP purposes, thereby increasing the reported sales and EPS growth rates to a substantial degree. I think this will happen no later than 2010 and it will be a catalyst for a significantly higher share price.
Biotech is more than just drugs, and MON deserves to be a core holding in every biotech investor’s portfolio, IMHO.
Market Data 
Markets 
AI
